SALT LAKE CITY--(BUSINESS WIRE)--Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases, today announced the upcoming presentation of a novel biomarker-driven clinical development strategy for their CDK9 inhibitor, alvocidib, in patients with acute myeloid leukemia (AML). This strategy takes advantage of the discovery of a biomarker associated with the MCL1-dependent mechanism of action of alvocidib in combination with standard chemotherapy agents in patients with AML. These findings will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 29 through June 2, 2015.
Help employers find you! Check out all the jobs and post your resume.
